Eligo Bioscience inks deal with GSK potentially worth up to $224 million

Eligo Bioscience inks deal with GSK potentially worth up to $224 million

Congratulations to #EligoBioscience for this partnership with GSK!
And a big thank you to Michèle Paquier, PI Director of Eligo Bio science who uses the PI Planner software from the company PI Motion SAS.

We are proud to announce a partnership worth up to $224M with GSK to develop a CRISPR-based microbiome therapy for the millions of patients suffering from acne every year.

Read the press release here: https://lnkd.in/eHjC-77